Loading company…
ViroGates A/S is a Danish company that develops and sells the suPARnostic biomarker test for assessing health risk.
Founded in 2001 in Denmark, ViroGates A/S develops and commercializes suPARnostic, a biomarker that measures soluble urokinase plasminogen activator receptor (suPAR) in blood to assess health risks. Its applications include acute care triage, clinical trials and wellness programs. In 2023 it reported revenue of DKK 810,366.70 and EBITDA of DKK -1,818,316.60. The company has raised DKK 14.5 mn from investors including PreSeed Ventures and SEED Capital and is listed at the Seed stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in